however, while this action can cause a risk for metabolic acidosis, this mechanism does not appear to be involved in the anticonvulsant action of the drug
Intramuscular injections allow for higher doses of ALA to be administered, and some research found that higher oral doses may have an anti-cancer effect
[DOI] [PubMed] [Google Scholar] 787
Timing Baseline Marker CRP Why it matters May help track broader inflammation when injury, gut symptoms, or systemic inflammation are part of the picture
Who responds best to CagriSema Ideal candidates: Significant obesity (BMI 30-40+) Previously plateaued on GLP-1s alone Need maximum weight loss Good GI tolerability Metabolic syndrome or diabetes Commitment to long-term use Excellent responders: Higher baseline weight (more to lose) Good adherence to protocol Combine with diet/exercise Younger patients (better metabolism) No significant medication interactions May respond less optimally: Very low starting weight (BMI 30%): Nausea (most common) Decreased appetite (intended effect) Constipation Fatigue (especially first months) Common (10-30%): Vomiting (if nausea not managed) Diarrhea (alternating with constipation) Abdominal pain/discomfort Headache Dizziness Less common ( 40 with comorbidities Insurance covers surgery Want permanent solution Don't want ongoing injections Sourcing cagrilintide and semaglutide Obtaining these peptides requires understanding current availability
It's a critical consideration, and the answer affects your health journey with TRT
